Mariam Jamal-Hanjani
Group Leader and Thoracic Oncologist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (39)
Year:
2026
S. Table 1: List of PEACE Consortium members. S. Table 2: Sample database used for the study for Panel, Exome and RNASeq samples. S. Table 3: Overview of lines of treatment given to each patient. S. Table 4: Lesions and patients included in the lesion-level response to ICI analysis. S. Table 5: Hallmark genesets significantly upregulated in normal tissue vs tumor tissue. Table shows p-values for tissue type, purity; T value for tissue type, purity; q-value for tissue type, purity (FDR corrected). S. Table 6: Hallmark genesets significantly upregulated in tumor tissue vs normal tissue. Table shows p-values for tissue type, purity; T value for tissue type, purity; q-value for tissue type, purity (FDR corrected). S. Table 7: Genes included in the target panel. S. Table 8: Tree topology comparisons between manually constructed trees and pairtree-constructed trees.
Year:
2025
Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or whole RNA sequencing. Supplementary figure 2: Phylogeny and WGD events in CRUKP1047. Supplementary figure 3: Ploidy and SCNA burden. Supplementary figure 4: Overview of each case. Supplementary figure 5: MEDICC2 copy number sample trees. Supplementary figure 6: MEDICC tree of all exome samples demonstrating that samples cluster together by patient, and not by melanoma subtype. Supplementary figure 7: SCNA frequency of cutaneous (a), acral (b) and melanoma of unknown primary (MUP, c). Supplementary figure 8: Correlation between liver copy number distance to other sites and time of emergence after stage IV diagnosis. Supplementary figure 9: Examination of tumour heterogeneity of alterations to antigen-presentation machinery genes,with site and patient annotation. Supplementary figure 10: Boxplots indicating the proportion of losses in the cohort for each segment. Supplementary figure 11: Balance of expression between nonsynonymous mutations that were not predicted to be neoantigens and clonal predicted neoantigens. Supplementary figure 12: Barplot of TIL infiltration score frequencies, determined by pathologist assessment of histology, across all samples. Supplementary figure 13: Number of samples per patient that are classified as either none-low in terms of TILs or moderate-heavy. Supplementary figure 14: Histogram of purity for samples with RNA-seq data. Supplementary figure 15: TME deconvolution. Supplementary figure 16: The effect of metastatic site on transcriptional profiles. Supplementary figure 17: Association of PHF3 copy number with expression. Supplementary figure 18: Overview of gene fusions identified in RNA-seq data. Supplementary figure 19: Comparison of ploidy estimates from panel sequencing data, exome data and FISH. Supplementary figure 20: Comparison of ploidy estimates in panel, exome, FISH and single cell data. Supplementary figure 21: FACs sort plot for CRUKP2567 diaphragmatic metastasis. Supplementary figure 22: Ploidy and wGII values from single cell sequencing of FACS-sorted tumour cells. Supplementary figure 23: Copy number profiles on chromosome 5 for bulk samples from primary and DI_2_R2, a diaphragmatic metastasis. Supplementary figure 24: Histogram of purity of samples for which RNA-seq was performed faceted by patient. Supplementary figure 25: Histogram of purity of samples for which RNA-seq was performed faceted by tissue site.
Year:
2025
Workflow of the study analysis. A, A total of 94 IDH wt GBMs were analyzed (35 from the PCAWG cohort and 59 from the GB-UK cohort). B, The core region of all patient tumors was analyzed using WGS, and GB-UK patient tumors were further subjected to multiregion DNA FISH and nascent RNAscope analysis to characterize spatial patterns of oncogenic ecDNAs. C, The ecDNA genetic landscape and fine structure were analyzed using WGS information, and mathematical modeling of single-cell copy number was employed to reconstruct evolutionary histories in GB-UK patient tumors. ( B, created using BioRender assets. https://BioRender.com/kgae4q5 ; https://BioRender.com/7f2pume )
Year:
2025
Oncogenes amplified on extrachromosomal DNA (ecDNA) contribute to treatment resistance and poor survival across cancers. Currently, the spatiotemporal evolution of ecDNA remains poorly understood. In this study, we integrate computational modeling with samples from 94 treatment-naive human glioblastomas (GBM) to investigate the spatiotemporal evolution of ecDNA. We observe oncogene-specific patterns of ecDNA spatial heterogeneity, emerging from random ecDNA segregation and differing fitness advantages. Unlike PDGFRA -ecDNAs, EGFR -ecDNAs often accumulate prior to clonal expansions, conferring strong fitness advantages and reaching high abundances. In corroboration, we observe pretumor ecDNA accumulation in vivo in genetically engineered mouse neural stem cells. Variant and wild-type EGFR -ecDNAs often coexist in GBM. Those variant EGFR -ecDNAs, most commonly EGFRvIII -ecDNA, always derive from preexisting wild-type EGFR -ecDNAs, occur early, and reach high abundance. Our results suggest that the ecDNA oncogenic makeup determines unique evolutionary trajectories. New concepts such as ecDNA clonality and heteroplasmy require a refined evolutionary interpretation of genomic data in a large subset of GBMs. Significance: We study spatial patterns of ecDNA-amplified oncogenes and their evolutionary properties in human GBM, revealing an ecDNA landscape and ecDNA oncogene–specific evolutionary histories. ecDNA accumulation can precede clonal expansion, facilitating the emergence of EGFR oncogenic variants, reframing our interpretation of genomic data in a large subset of GBMs. See related commentary by Korsah et al., p. 1979
Year:
2025
Simulating multi-ecDNA dynamics in vivo. A, DNA FISH and nascent RNAscope images from the tumor of patient A5, showing the coexistence of both EGFR -ecDNA and PDGFRA -ecDNA. B, Circular structures of three distinct oncogenic ecDNAs detected in the tumor of patient A5. C, GBMs in the GB-UK and PCAWG cohorts containing more than one oncogenic species and their respective copy numbers. D, In a multiple-ecDNA application of SPECIES, the clone-initiating cell begins with k 1 and k 2 copies of ecDNA 1 and ecDNA 2, respectively. E, Representation of the impacts of ecDNA cosegregation and coselection on the number of inherited ecDNA copies during cell division. Cosegregation drives correlated inheritance of both ecDNA types, whereas coselection favors tumor cells carrying at least one copy of each type. F, Application of SPECIES to simulate two separate ecDNA species. Simulated tumors were initialized with a single cell, carrying k 1 and k 2 copies of each ecDNA species. Representative model images show examples of low and high cosegregation and coselection. G and H, Parameter inference summary for the tumor of patient A5, for which we measured both the EGFR -ecDNA and PDGFRA -ecDNA copy-number distributions using DNA FISH, using multiple-ecDNA SPECIES. Parameters s p and s m represent selection coefficients for tumor cells with 1 (pure) or 2 (mixed) ecDNA species, respectively. I, Comparison of inferred k and k 1 values for all patient tumors confirmed by WGS to harbor two or more ecDNA species. J, The presence of ecDNA amplifications may be used to aid stratification, given that oncogenes on ecDNA have an inherent resistance mechanism through the ability of ecDNA to dynamically adjust copy number in response to targeted agents. Earlier monitoring and intervention are recommended for those patient tumors with ecDNA that will receive targeted therapies.
Year:
2025
Selection dynamics of EGFR SVs on ecDNA. A, A subclonal EGFRvIII variant on ecDNA in the tumor of patient A23. B, Variant heteroplasmy in the core region of all samples across the GB-UK and PCAWG cohorts, which contained EGFR variant–bearing ecDNA. C, Effects of (i) pre- and (ii) postclonal expansion mutation of EGFR -ecDNA on its resulting spatial pattern in the expanded tumor. D, SPECIES was applied to simulate the emergence of an advantageous EGFRvIII mutation on ecDNA, either prior to or after the onset of clonal expansion of the tumor. The example shown is for a pre-expansion mutation, with parameters ( k w t = 20 , k v a r = 1 , V v a r = 0 ). The SD of ecDNA heteroplasmy is shown by the shaded region in the lower plot. E, Model predictions for resulting variant heteroplasmy in a tumor for a range of wild type- and variant-bearing ecDNA copy numbers in the clone-initiating tumor cell (for pre-expansion EGFR mutation) and mutation times (for post-expansion EGFR mutation). The red-shaded region denotes parameter combinations inconsistent with observed patient core heteroplasmy values. Mean ± variance is derived from 1,000 simulated tumors. F, SPECIES model predictions for the probability of observing EGFRvIII ecDNA across tumor core and margin, for a pair of core and random margin regions. Mean values are derived from 1,000 simulated tumors. G, (Top) IHC slide for the tumor of patient A20, showing the presence of EGFRvIII in the tumor core and infiltrating margin (blue = hematoxylin; brown = EGFRvIII ). (Bottom) Summary of EGFRvIII in core and margins of GB-UK cohort samples, determined by IHC. H, Variant allele frequencies of point mutations within EGFR in PCAWG samples harboring EGFR -ecDNA. Red lines represent the frequency expected for a mutation carried by all ecDNAs within a sample. I, Distributions of EGFR wt-ecDNA abundance in the cell that acquires the first mutation, for a range of ecDNA mutation rates. Patient tumor values are derived from their respective inferred k values, assuming that the arrival of a mutation on ecDNA initiates clonal expansion, implying that the number of EGFR wt-ecDNA in the mutating cell is thus equal to k − 1 (with the remaining one ecDNA carrying the mutated allele). J, Timeline of EGFR -ecDNA tumorigenesis. ( i ) Initial EGFR wt-ecDNA is generated and accumulates in precancerous cells, conferring a moderately positive selective advantage. In time, the EGFRvIII mutation occurs on one of the accumulated EGFR wt-ecDNAs, conferring a strong positive advantage. ( ii ) Reconstructed ecDNA structures from the tumor of GB-UK patient A5 confirm that EGFR wt and EGFRvIII ecDNAs share common breakpoints, indicating that EGFRvIII arose from the mutation of an existing EGFR wt-ecDNA. (iii) EGFRvIII -ecDNA further promotes clonal expansion, driving tumor growth.
Year:
2025
SPECIES spatial modeling of ecDNA evolution. A and B, DNA FISH staining of two representative GBM samples from the GB-UK cohort, revealing ( A ) EGFR - and ( B ) PDGFRA -ecDNA. EGFR -ecDNA seem to congregate into “hubs” (white arrows). Single-cell ecDNA copy-number distributions are derived from DNA FISH images using unbiased image analysis. C, (i) SPECIES is initiated with a single tumor cell containing k copies of ecDNA. (ii) Model of ecDNA selection. Cells carrying one or more copies of ecDNA divide at a rate s faster than cells lacking ecDNA. (iii) Cells push neighbors within a radius q on the lattice to make space required for cell division. D, Spatial computational model of ecDNA-driven tumors. ABC was used to infer optimal model parameters for the initial number of ecDNA, k ; ecDNA-conferred selection, s ; and cell pushing strength, q , for a given set of patient tumor measurements. E and F, Example output of the ABC model fitting algorithm using ( E ) 2 and ( F ) 3 spatial regions. (Left to right) Inferred k , s , and q and model best-fit distributions for each tumor region. The sum of the Wasserstein distance between patient and simulated distributions for each tumor region, representing closeness of fit, is denoted by σ. G, Comparison of inferred k , s , and q when analyzing 2 (core and margin) vs. 3 (core, margin, and leading edge) spatial regions. H, Summary of inferred model parameters for all sampled human GBM tumors. The highlighted color represents ecDNA-amplified oncogenes ( EGFR , PDGFRA , or CDK4 ) in each tumor. I, Inferred model parameters for all patient tumors (excluding the tumor of patient A5, which contained separate EGFR- and PDGFRA -ecDNA species), stratified by ecDNA-amplified oncogene ( EGFR or PDGFRA ). ( D, created using BioRender assets. https://BioRender.com/7f2pume )
Year:
2025
Diversity and high copy numbers of ecDNA in IDH wt GBMs. A, Focal copy-number amplifications across the GB-UK and PCAWG cohorts, categorized by amplicon type [ecDNA, breakage–fusion–bridge (BFB) cycle, linear]. Only tumors containing focal amplifications are shown. Oncogenes with the same colored box indicate they exist on the same ecDNA molecule. The horizontal line between patients A61 and A3 (GB-UK) and patients SP27603 and SP23622 (PCAWG) separates patient samples with (above) or without (below) ecDNA, detected by WGS, DNA FISH, or nascent RNAscope. Oncogenes tested with DNA FISH and/or nascent RNAscope, EGFR , PDGFRA , and CDK4 , are separated to the left of the vertical dashed line. B, Median ecDNA copy number vs. number of ecDNA-amplified genes for GB-UK and PCAWG cohorts (Spearman correlation). C, Oncogenes contained within ecDNA in both GB-UK and PCAWG cohorts ranked by maximum copy number. The number of samples with each oncogene as ecDNA in the GB-UK cohort is described in brackets. Only copy numbers detected by WGS are shown here. D, Mean copy number of linear focal amplifications vs. ecDNA in GB-UK. E, Mean copy number of non-oncogenes compared with oncogenes amplified on ecDNA in GB-UK. F, Complexity score of linear focal amplifications vs. ecDNA in GB-UK. G, Number of uni- and multichromosomal ecDNAs in GB-UK and PCAWG cohorts. H, Distribution of ecDNA lengths in GB-UK and PCAWG cohorts. I, Median ecDNA copy number vs. length of intergenic DNA for EGFR -ecDNA in GB-UK and PCAWG cohorts (Spearman correlation).
Year:
2025
ecDNA accumulation in genetically engineered in vivo and ex vivo murine models. A, Neural stem cells were propagated within the SVZ of genetically engineered mice for 4 months. B, Myc - ecDNAs were induced in adult murine neural stem cells, which were then cultured ex vivo for 5 weeks. C, DNA FISH analysis of neural stem cells within the SVZ of genetically engineered mice (i) without Myc -ecDNA ( Myc +/+ ; P53 fl/fl ; Nestin-Cre , n = 2) and (ii) with Myc -ecDNA ( Myc ec/+ ; p53 fl/fl ; Nestin-Cre , n = 2), both on a background of homozygous Trp53 loss. D, ecDNA copy-number dynamics in murine adult neural stem cells (data from ref. 33 ) with corresponding simulated dynamics, assuming either neutral or positively selected ecDNA. ( A and B, created using BioRender assets. https://BioRender.com/a1hpt9n .)
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (42)
Alessandro Di Federico
University of Bologna
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Philip Hobson
Deputy Head of Flow Cytometry
The Francis Crick Institute
Yinyin Yuan
Institute of Cancer Research Sutton
Mihaela Angelova
The Francis Crick Institute
Vineet Bafna
Professor
University of California, San Diego
Naftali Kaminski
Chief, Pulmonary, Critical Care aand Sleep Medicine
Yale University
Giulio Caravagna
Tenure-track researcher
University of Trieste
Charles Swanton
Chief Clinician
-
Julian Downward
Associate Research Director
The Francis Crick Institute
Andrea Ventura
Member
Memorial Sloan Kettering Cancer Center
James Larkin
Professor
-
Ruggero De Maria
Deputy Director
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Benjamin Werner
Reader in Somatic Evolution
Barts Cancer Institute
Clare Puttick
The Francis Crick Institute
Kevin Litchfield
University College London
Hanyun Zhang
Garvan Institute of Medical Research
Giulia Bon
Staff Scientist
IRCCS Regina Elena National Cancer Institute
Scott Shepherd
The Francis Crick Institute
Ariana Huebner
University College London
Selvaraju Veeriah
University College London
Krijn Dijkstra
The Netherlands Cancer Institute
JAMES READING
University College London
Katey Enfield
Assistant Professor
The University of British Columbia
Thomas Santarius
University of Cambridge
Allan Hackshaw
University College London
Matthew Jones
Assistant Professor
Massachusetts Institute of Technology
Rachel Chambers
University College London
Howard Y. Chang
Stanford University School of Medicine
Clare Weeden
The Francis Crick Institute
Delphine Boche
Professor of Neuroimmunopathology
University of Southampton
Weini Huang
Senior Lecturer
Queen Mary University of London
Fiona Byrne
The Francis Crick Institute
Shan E Ahmed Raza
Associate Professor
University of Warwick
Khalid AbdulJabbar
Institute of Cancer Research
John Le Quesne
Professor of Molecular Pathology
University of Glasgow
Floris Foijer
Scientific Staff
University Medical Center Groningen
Sergio Quezada
University College London
Paul S. Mischel
Stanford University School of Medicine
Erik Sahai
The Francis Crick Institute
Mary Green
Deputy Head of Experimental Histopathology
The Francis Crick Institute
Hang Xu
Genentech Inc
Make your next move.
Prepare your application
Review drafts before you send them.